• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期不进展者对1型人类免疫缺陷病毒的中和及感染增强抗体反应

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

作者信息

Montefiori D C, Pantaleo G, Fink L M, Zhou J T, Zhou J Y, Bilska M, Miralles G D, Fauci A S

机构信息

Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

J Infect Dis. 1996 Jan;173(1):60-7. doi: 10.1093/infdis/173.1.60.

DOI:10.1093/infdis/173.1.60
PMID:8537683
Abstract

Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors (LTNPs) and non-LTNPs were evaluated for virus neutralization and infection enhancement in vitro. Sera from LTNPs had higher average titers of neutralizing antibodies to HIV-1 strains IIIB and MN and more frequently neutralized primary isolates from progressors (14.9% vs. 1.3%, P = .002). Replication-competent HIV-1 was isolated from peripheral blood mononuclear cells and lymph nodes of 3 LTNPs. All viruses from LTNPs had a non-syncytium-inducing phenotype, were resistant to neutralization by autologous serum obtained at the time of virus isolation, and showed little evidence of a heightened sensitivity to neutralization by heterologous sera. Complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-1IIIB and primary isolates was equally prevalent for sera from LTNPs and non-LTNPs. Results indicate that LTNPs produce vigorous serum antibody responses and that long-term nonprogression is not associated with homologous neutralization or the absence of C'-ADE.

摘要

对来自人类免疫缺陷病毒1型(HIV-1)感染的长期不进展者(LTNP)和非LTNP的血清抗体进行体外病毒中和及感染增强评估。LTNP的血清对HIV-1毒株IIIB和MN具有更高的平均中和抗体滴度,且更频繁地中和来自进展者的原始分离株(14.9%对1.3%,P = 0.002)。从3名LTNP的外周血单核细胞和淋巴结中分离出具有复制能力的HIV-1。来自LTNP的所有病毒均具有非合胞体诱导表型,对病毒分离时获得的自体血清的中和作用具有抗性,并且几乎没有证据表明对异源血清的中和作用高度敏感。HIV-1IIIB和原始分离株的补体介导的抗体依赖性增强(C'-ADE)在LTNP和非LTNP的血清中同样普遍。结果表明,LTNP产生强烈的血清抗体反应,并且长期不进展与同源中和或不存在C'-ADE无关。

相似文献

1
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.长期不进展者对1型人类免疫缺陷病毒的中和及感染增强抗体反应
J Infect Dis. 1996 Jan;173(1):60-7. doi: 10.1093/infdis/173.1.60.
2
Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.泰国感染env基因B亚型和E亚型病毒的个体血浆中针对1型人类免疫缺陷病毒原始分离株的中和抗体和增强抗体分析。
Viral Immunol. 1996;9(3):175-85. doi: 10.1089/vim.1996.9.175.
3
Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.两组人类免疫缺陷病毒1型(HIV-1)感染的长期不进展者血清对原发性HIV-1分离株的中和活性增强。
J Infect Dis. 1997 Nov;176(5):1180-7. doi: 10.1086/514111.
4
Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.长期不进展者体内抗人类免疫缺陷病毒1型抗体的体外产生模式
Clin Immunol Immunopathol. 1997 Dec;85(3):320-3. doi: 10.1006/clin.1997.4470.
5
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.原发性感染和长期非进展性感染中针对1型人类免疫缺陷病毒的中和抗体反应。
J Infect Dis. 1997 Oct;176(4):924-32. doi: 10.1086/516508.
6
Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.描述一组长期非进展者体内针对 HIV-1 的广谱中和抗体反应。
PLoS One. 2018 Mar 20;13(3):e0193773. doi: 10.1371/journal.pone.0193773. eCollection 2018.
7
Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase.病毒体结合的细胞间黏附分子-1和活化的淋巴细胞功能相关抗原-1:一组独立于疾病状态和阶段而赋予对1型人类免疫缺陷病毒感染个体血清中和作用抗性的因素组合。
Clin Immunol. 2003 Aug;108(2):111-8. doi: 10.1016/s1521-6616(03)00093-7.
8
Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.抗体介导的对人免疫缺陷病毒1型外周血单核细胞原代分离株的中和作用不受细胞初始激活状态的影响。
J Virol. 1997 Mar;71(3):2512-7. doi: 10.1128/JVI.71.3.2512-2517.1997.
9
Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.在血清转化后不久获得的人类免疫缺陷病毒(HIV)阳性血清可中和原代巨噬细胞上的自体1型HIV分离株,但不能中和淋巴细胞上的该分离株。
J Virol. 2000 Jun;74(12):5403-11. doi: 10.1128/jvi.74.12.5403-5411.2000.
10
Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort.血友病队列中1型人类免疫缺陷病毒的长期非进行性感染
J Infect Dis. 1999 Dec;180(6):1790-802. doi: 10.1086/315128.

引用本文的文献

1
Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.通过糖基工程改造冠状病毒聚糖护盾以呈现 α-半乳糖表位,增强潜在的 Covid-19 疫苗的免疫原性。
Vaccine. 2020 Sep 29;38(42):6487-6499. doi: 10.1016/j.vaccine.2020.08.032. Epub 2020 Aug 19.
2
Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.多种抗体克隆均可提高 HIV-1 中和广度,而每种克隆的中和广度有限。
PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.
3
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.
增强抗HIV抗体的临床潜力及应用
Front Immunol. 2017 Nov 28;8:1655. doi: 10.3389/fimmu.2017.01655. eCollection 2017.
4
Non-Neutralizing Antibodies Directed against HIV and Their Functions.针对HIV的非中和抗体及其功能
Front Immunol. 2017 Nov 20;8:1590. doi: 10.3389/fimmu.2017.01590. eCollection 2017.
5
Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines.筛选原发性 gp120 免疫原,以制定下一代多价 DNA 疫苗-蛋白疫苗 HIV-1 疫苗。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2996-3009. doi: 10.1080/21645515.2017.1380137. Epub 2017 Sep 21.
6
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.V1V2特异性补体激活血清IgG作为RV144中HIV-1感染风险降低的一个相关因素。
PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017.
7
Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.针对HIV-1的广泛中和抗体作为免疫反应的一个新方面
Acta Naturae. 2015 Oct-Dec;7(4):11-21.
8
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.传播的病毒适应性和宿主T细胞反应共同决定了两名HIV-1感染者不同的感染结果。
PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.
9
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.丝状病毒相关载体(IAV)的结构洞察以及基于IAV的诱导体液和细胞免疫反应疫苗的开发:对HIV-1疫苗的启示
Viruses. 2014 Dec 17;6(12):5047-76. doi: 10.3390/v6125047.
10
HIV-1 neutralizing antibodies: understanding nature's pathways.HIV-1 中和抗体:理解自然途径。
Immunol Rev. 2013 Jul;254(1):225-44. doi: 10.1111/imr.12075.